


What Is Claimed Is:

1. A compound of Formula I:



Formula I



wherein W, X, Y and Z are each independently selected
5 from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) and that no more than two of W, X, Y and Z are N;


wherein R₃, R₄, R₅ and R₆ are each independently hydrogen, hydroxy, sulfhydryl, lower alkoxy (1-4 carbon atoms), lower thioalkoxy (1-4 carbon atoms), lower alkyl (1-4 carbon atoms), halo, CN, CF₃, NO₂, COOR, or NR₇R₈;

10 wherein R₇ and R₈ are independently hydrogen or lower alkyl (1-4 carbon atoms);

M is oxygen or sulfur;

A is selected from the group consisting of:














wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1 ;
 R_1 and R_2 independently are:
an alkyl of 1 to 6 carbon atoms,

Sub
B

- unsubstituted, mono or polysubstituted phenyl or polyaromatic,
5 unsubstituted, mono or polysubstituted heteroaromatic,
 with hetero atom(s) N (nitrogen), O (oxygen) and/or S (sulfur) or,
 unsubstituted, mono or polysubstituted aralkyl,
 unsubstituted, mono or polysubstituted cyclo or polycycloalkyl hydrocarbon, or
 mono or polyheterocycle (3 to 8 atoms per ring) with one
10 to four hetero atoms as N (nitrogen), O (oxygen) or S (sulfur); and
 wherein the substitutions are selected from
 - hydrogen
 - lower alkyl of 1-4 carbon atoms,
15 - $(CH_2)_iOR_{13}$
 - $(CH_2)_iSR_{13}$
 - trifluoromethyl
 - nitro
 - halo
20 - cyano
 - azido
 - acetyl



*Sub
B'*



- $(CH_2)_i$ - tetrazole, and
- polyhydroxy alkyl or cycloalkyl of from 5 to 8 carbon atoms,

Sub, B

wherein i and j are independently 0, 1, 2,
 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower
alkyl (1-4 carbon atoms), alkaryl of from 7 to 10 carbon
atoms;

5 $NR_{13}R_{14}$ is also mono or bicyclic ring with one
to four hetero atoms as N, O, S;

provided that when W, X, Y and Z are each C- R_3 ,
C- R_4 , C- R_5 and C- R_6 and R_3 , R_4 , R_5 and R_6 are hydrogen and

10 A is $\text{NH}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ and R_1 is unsubstituted phenyl, then R_2
cannot be unsubstituted phenyl;

further provided that when W, X, Y and Z are
each C- R_3 , C- R_4 , C- R_5 , and C- R_6 and R_3 , R_4 , R_5 and R_6 are
15 hydrogen or halogen and

A is $\text{NH}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{NH}-$, and
M is oxygen, and

20 R_2 is unsubstituted or mono substituted phenyl and
wherein substitution is chloro, bromo, butyl, n-butoxy,
iso-butoxy, then R_1 cannot be unsubstituted or mono
substituted phenyl, or unsubstituted naphthyl wherein
substitution is chloro or bromo;

25 furthermore provided that when W, X, Y and Z
are each C- R_3 , C- R_4 , C- R_5 , and C- R_6 and R_3 , R_4 , R_5 and R_6
are hydrogen or halogen and


30 A is $\text{NH}-\overset{\text{S}}{\underset{\parallel}{\text{C}}}-\text{NH}-$, and
M is oxygen, and
 R_1 is unsubstituted phenyl, unsubstituted benzyl,
unsubstituted naphthyl or mono substituted phenyl
wherein substitution is halogen, methyl, n-butyl or
methoxy, then R_2 cannot be: a) unsubstituted phenyl; b)
35 unsubstituted naphthyl; c) unsubstituted benzyl; d) mono

Sub
B'

substituted phenyl wherein substitution is halogen, methyl, n-butoxy, iso-butoxy, or methoxy; or e) disubstituted phenyl wherein substitution is methyl.

2. The compound of claim 1 wherein:

5 W and Y are each independently C-R₃, C-R₅ or N,
X and Z are each independently C-R₄ or C-R₆,
wherein R₃, R₄, R₅ and R₆ are each independently
chlorine, bromine, iodine, carbmethoxy, carboxy, meth-
oxy, methyl, thio, thiomethyl, thioethyl, and hydroxy;
10 M is O or S;
A is selected from



wherein R₁₁ and R₁₂ are independently hydrogen or alkyl of
from 1 to 4 carbon atoms, n is 0 or 1;

35 R₁ and R₂ are independently an unsubstituted,
mono or polysubstituted

*Sub
B'*

phenyl,

pyridyl,

pyrrolyl,

furanyl,

5 thiofuranyl,

pyrimidinyl,

indolyl,

quinolinyl,

quinazolinyl; or

10 a cyclo or polycycloalkyl hydrocarbon of 6 to 12 carbon atoms;

wherein the substituents are of claim 1, having up to three substituents per ring.

3. The compound of claim 1 wherein:

15 W is C-R₃ or N wherein R₃ is selected from hydrogen, chlorine, bromine, iodine, methoxy, and methyl;


20 X is C-R₄ wherein R₄ is selected from hydrogen, chlorine, hydroxy, methoxy, sulfhydryl and thioethyl-ether;

Y is C-R₅ wherein R₅ is selected from hydrogen, chlorine, bromine, iodine, methoxy, methyl, carboxy, and carbmethoxy;


Z is C-R₆ and N, wherein R₆ is hydrogen;

25 M is oxygen or sulfur;

A is selected from



Sub B'




wherein R_{11} and R_{12} are hydrogen;
n is 0 or 1;
R₁ and R₂ are independently phenyl,
mono or polysubstituted phenyl,
25 pyridyl,
 pyrrolyl,
 furanyl,
 thiofuranyl,
 pyrimidinyl,
30 indolyl,
 quinolinyl,
 quinaxolinyl;
 wherein substitutions are the same as in claim
1.

Sulf B

4. The compound of claim 1 wherein:

M is sulfur.


A is



and W, X, Y, Z, R₁ and R₂ are as in claim 1.


C

5. The compound of claim 4 having the
structure:



Q

6. The compound of claim 4 having the
10 structure:




Sulf B

7. The compound of claim 1 wherein:

M is oxygen;


A is




*Sub
B.D*

~~W, X, Y, and Z are selected from C-R₃, C-R₄, C-R₅, C-R₆ and N and at least one and no more than two of W, X, Y and Z are N. R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1.~~

C 5 8. The compound of claim ~~1~~ ⁵⁴ having the structure:




C 9. The compound of claim ~~1~~ ⁵⁴ having the structure:



*Sub
B3*

10. The compound of claim 1 having the structure:



wherein R_x is hydroxy, sulfhydryl, lower alkoxy (1-4 carbon atoms), lower thioalkoxy (1-4 carbon atoms),
5 lower alkyl (1-4 carbon atoms), halo, CN, CF_3 , NO_2 , $COOR$, or NR_xR_8 , where $x=0-3$;

wherein R_x and R_8 are independently hydrogen or lower alkyl (1-4 carbon atoms);


R_1 and R_2 are as defined in Formula I.

10 11. The compound of claim 1 wherein:

W , X , Y and Z are selected from $C-R_3$, $C-R_4$, $C-R_5$ and $C-R_6$;

M is oxygen;

A is




15 R_1 and R_2 cannot both be phenyl in the same compound; and R_3 , R_4 , R_5 and R_6 are as defined in claim 1.

12. The compound of claim 1 wherein:


M is S (sulfur);

20 W , X , Y , Z , R_1 and R_2 are as defined in claim 1; and

A is



having the structure:




13. The compound of claim 1 wherein:

W, X, Y and Z are selected from C-R₃, C-R₄, C-R₅, C-R₆ and N and at least one and no more than two W, X, Y and Z
5 are N;

R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1;


M is oxygen; and

A is



10

having the structure:



B

14. The compound of claim 1 wherein:

W, X, Y and Z are selected from C-R₃, C-R₄, C-R₅, and C-R₆ wherein R₃, R₄, R₅ and R₆ are as defined in claim 1 except
15 none can be hydrogen or halogen;

M is oxygen;

Sub
B4

Subj B

A is $\begin{array}{c} \text{S} \\ \parallel \\ \text{NH}-\text{C}-\text{NH}- \end{array}$, and
R₁ and R₂ are as defined in claim 1.

5 15. The compound of claim 1 wherein:
W, X, Y and Z are selected from C-R₃, C-R₄, C-R₅, C-R₆,
wherein R₃, R₄, R₅ and R₆ are independently selected from
hydrogen and halogen;

10 M is oxygen;

A is $\begin{array}{c} \text{S} \\ \parallel \\ \text{NH}-\text{C}-\text{NH}- \end{array}$.

Subj S

15 16. The compound of claim 1 wherein:
W, X, Y, and Z are each independently selected
from C-R₃, C-R₄, C-R₅, C-R₆ and wherein R₃, R₄, R₅ and R₆
are independently selected from hydroxy, sulfhydryl,
lower alkoxy, lower thioalkoxy, lower alkyl, CN, CF₃,
NO₂, COOR₇, NR₇R₈, wherein R₇ and R₈ are as defined in
claim 1;

20 M is oxygen; and

R₁ and R₂ are as defined in claim 1.

25 17. The compound of claim 1 wherein:
W, X, Y and Z are each independently selected
from C-R₃, C-R₄, C-R₅, C-R₆ and wherein R₃, R₄, R₅ and R₆
are as defined above but they cannot be hydrogen or
halogen;

M is oxygen;


30 A is $\begin{array}{c} \text{O} \\ \parallel \\ \text{NH}-\text{C}-\text{NH}- \end{array}$; and

R₁ and R₂ are as defined in claim 1.

3d

18. The compound of claim 7 wherein:


- R_{13} and R_{14} are each independently methyl, ethyl, t-butyl,
- R_{15} and R_{16} are each independently methyl, and
- 5 - $NR_{13}R_{14}$ is selected from:




where R_{17} is alkyl of 1 to 3 carbon atoms.

19. The compound of claim 1 wherein:


A is



R₁ is



or



R_{13} and R_{14} are each independently selected from hydrogen, methyl, ethyl, t-butyl, and benzyl;


15 wherein R_{15} and R_{16} are independently selected from hydrogen, methyl and ethyl;

i is 0 or 1;

M is O (oxygen); and

W, X, Y, Z and R_2 are as defined in claim 1.

B
20. The compound of claim 1 having the structure and meanings for R as indicated:



wherein R is selected from the group consisting of:

- a) 4-BrPh;
- 5 b) 4-COOEt-Ph;
- c) 4-CF₃Ph;
- d) 3-Me-Ph;
- e) 3,5-dichloro-4-pyridinyl;
- f) 3-COOEt-Ph;
- 10 g) 3-COOtBu-Ph;
- h) 3-COOH-Ph;
- i) 4-MeO-Ph;
- j) 3-MeO-Ph;
- k) 2-MeO-Ph; and
- 15 l) C₆H₅.

50

21. The compound of claim 1 is selected from:
Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-;
20 *Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-ethyl ester;*

- Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxy-phenyl)-;
- 5 Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxy-phenyl)-;
- 10 Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxy-phenyl)-;
- 15 Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[(4-trifluoromethyl)phenyl]-;
- 20 Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-, 1,1-dimethylethyl ester;
- B
B
- 25 Hydrazinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl];
- 30 Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]- ethyl ester;
- 25 Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-, ethyl ester; and
- 30 Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-.

*Sub
B.1*

22. The compound of Claim 1 is selected from the group consisting of:

2-Thioxo-3-o-tolyl-2,3-dihydro-1H-quinazolin-4-one
3-(2-Ethyl-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4
5 -one
3-(4-Chloro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin
-4-one
3-(2,3-Dichloro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazo
lin-4-one
10 3-(3-Fluoro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin
-4-one
3-Naphthalen-1-yl-2-thioxo-2,3-dihydro-1H-quinazolin-4
-one
15 3-(3-Methoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin
-4-one
2-Hydrazino-3-(3-methoxy-phenyl)-3H-quinazolin-4-one
3-(3-Dimethylamino-phenyl)-2-thioxo-2,3-dihydro-1H
-quinazolin-4-one
20 3-[4-(Morpholine-4-sulfonyl)-phenyl]-2-thioxo-2,3
-dihydro-1H-quinazolin-4-one
3-Pyridin-3-yl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one
3-(4-Methoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin
-4-one
25 3-(3-Nitro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4
-one
3-(3-Isopropoxy-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido
[2,3-d]pyrimidin-4-one
3-(3,4-Dimethoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinaz
olin-4-one

30 23. The compound of Claim 1 is selected from the group consisting of:

2-Hydrazino-3-o-tolyl-3H-quinazolin-4-one
3-(2-Ethyl-phenyl)-2-hydrazino-3H-quinazolin-4-one

Sab
B

- 3 - (4-Chloro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3 - (2,3-Dichloro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3 - (3-Fluoro-phenyl) -2-hydrazino-3H-quinazolin-4-one
2-Hydrazino-3-naphthalen-1-yl-3H-quinazolin-4-one
5 2-Hydrazino-3 - (3-methoxy-phenyl) -3H-quinazolin-4-one
3 - (3-Fluoro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3 - (3-Dimethylamino-phenyl) -2-hydrazino-3H-quinazolin-4-one
2-Hydrazino-3 - [4 - (morpholine-4-sulfonyl) -phenyl] -3H
10 -quinazolin-4-one
2-Hydrazino-3-pyridin-3-yl-3H-quinazolin-4-one
2-Hydrazino-3 - (4-methoxy-phenyl) -3H-quinazolin-4-one
3 - (3-Amino-phenyl) -2-hydrazino-3H-quinazolin-4-one
2-Hydrazino-3 - (3-isopropoxy-phenyl) -3H-pyrido[2,3
15 -d]pyrimidin-4-one
3 - (3,4-Dimethoxy-phenyl) -2-hydrazino-3H-quinazolin-4-one

24. The compound of Claim 1 wherein R₂ is unsubstituted, mono or polysubstituted phenyl or polyaromatic,






- 20 unsubstituted, mono or polysubstituted heteroaromatic, with hetero atom(s) N (nitrogen), O (oxygen) and/or S (sulfur) or, unsubstituted, mono or polysubstituted aralkyl, unsubstituted, mono or polysubstituted cyclo or 25 polycycloalkyl hydrocarbon, or mono or polyheterocycle (3 to 8 atoms per ring) with one to four hetero atoms as N (nitrogen), O (oxygen) or S (sulfur); and

wherein the substitutions are selected from

- 30 - hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂)_iOR₁₃
- (CH₂)_iSR₁₃



5

- Sub
B7*
- trifluoromethyl
 - nitro
 - halo
 - cyano
 - azido
 - acetyl




, and


Sub
B



B C 24
25. The compound of Claim 21 wherein R_2 is




wherein $-NR_{13}R_{14}$ is selected from



wherein R_{17} is alkyl of 1 to 3 carbon atoms.

26. A compound having the structure:









Sub B 8


wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) wherein no more than two of W, X, Y and Z are N;

M is oxygen or sulfur;

5 A is selected from the group consisting of:



*Suit
B*



15 wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1 ;
16 R_1 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are as defined in
claim 1; and
17 R_{17} is an alkyl of 1 to 3 carbon atoms.

20 27. The compound of claim 26 wherein
A is $-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-$; and
M is oxygen.




25 28. The compound of claim 26 wherein W, X, Y
and Z are each independently selected from C-R₃, C-R₄, C-
R₅ and C-R₆,




30 A is $-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}-$;
M is oxygen; and
 R_{17} is i-propyl.

62

29. The compound of claim 26 wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅ and C-R₆ and R₃, R₄, R₅ and R₆ are hydrogen,

- 5 A is $-\text{NH}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{NH}-$;
- M is oxygen;
- R₁₇ is i-propyl;
- R₁ is mono or polysubstituted phenyl wherein substitution
10 is selected from
- hydrogen
 - lower alkyl of 1-4 carbon atoms,
 - (CH₂)_iOR₁₃
 - (CH₂)_iSR₁₃
 - 15 - trifluoromethyl
 - nitro
 - halo
 - cyano
 - azido
 - 20 - acetyl





- $(CH_2)_i$ - tetrazole, and

- polyhydroxy alkyl or cycloalkyl of from 5 to 8 carbon atoms,


wherein i and j are independently 0, 1, 2,

5 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alkyl (1-4 carbon atoms), alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

10 30. A pharmaceutical composition comprising
an effective therapeutic amount of the compound of
Formula I and a pharmaceutically acceptable salt thereof

with a pharmaceutically acceptable carrier in unit dosage form:



Formula I



wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) and that no more than two of W, X, Y and Z are N;


wherein R₃, R₄, R₅ and R₆ are each independently hydrogen, hydroxy, sulfhydryl, lower alkoxy (1-4 carbon atoms), lower thioalkoxy (1-4 carbon atoms), lower alkyl (1-4 carbon atoms), halo, CN, CF₃, NO₂, COOR, or NR₇R₈;

wherein R₇ and R₈ are independently hydrogen or lower alkyl (1-4 carbon atoms);

M is oxygen or sulfur;







A is selected from the group consisting of:





wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1;

R₁ and R₂ independently are:
an alkyl of 1 to 6 carbon atoms,
unsubstituted, mono or polysubstituted phenyl or
polyaromatic,
5 unsubstituted, mono or polysubstituted heteroaromatic,
 with hetero atom(s) N (nitrogen), O (oxygen) and/or S
 (sulfur) or,
unsubstituted, mono or polysubstituted aralkyl,
unsubstituted, mono or polysubstituted cyclo or
10 polycycloalkyl hydrocarbon, or
mono or polyheterocycle (3 to 8 atoms per ring) with one
to four hetero atoms as N (nitrogen), O (oxygen) or S
 (sulfur); and
 wherein the substitutions are selected from
15 - hydrogen
 - lower alkyl of 1-4 carbon atoms,
 - (CH₂)_iOR₁₃
 - (CH₂)_iSR₁₃
 - trifluoromethyl
20 - nitro
 - halo
 - cyano
 - azido
 - acetyl



wherein i and j are independently 0, 1, 2,
R₁₃, R₁₄, R₁₅, R₁₆ are each independently hydrogen, lower
alkyl, alkaryl or from 7 to 10 carbon atoms; and
NR₁₃R₁₄ is also mono or bicyclic ring with one
5 to four hetero atoms as N,O,S.

31. A method for treating a condition advantageously affected by the binding of a compound of Formula I to a CCK receptor in a mammal in need of such treatment comprising providing an effective binding amount of the compound of Formula I according to claim 10 30.

32. A method of suppressing appetite in a mammal, comprising administering an effective appetite suppressing amount to a mammal in need thereof a compound of Formula I according to claim 15 30.

33. A method of reducing gastric acid secretion in a mammal comprising administering an effective gastric acid secretion reducing amount to a mammal in need thereof a compound of Formula I according to claim 20 30.

34. A method of reducing anxiety in a mammal, comprising administering an effective anxiety reducing amount to a mammal in need thereof a compound of Formula I according to claim 30.

25 35. A method for treating gastrointestinal ulcers in a mammal comprising administering an effective gastrointestinal ulcer treating amount to a mammal in need thereof a compound of Formula I according to claim 30.

36. A method of treating psychosis in a mammal comprising administering an effective psychosis treating amount to a mammal in need thereof a compound of Formula I according to claim 30.

5 37. A method of blocking drug or alcohol withdrawal reaction in a mammal comprising administering an effective withdrawal reaction blocking amount to a mammal in need thereof a compound of Formula I according to claim 30.

10 38. A method of treating pain in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I according to claim 30.

15 39. A method of treating and/or preventing panic in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I according to claim 30.

20 40. A method of diagnosis of gastrin-dependent tumors in a mammal, comprising administering to the mammal in need thereof an effective diagnosing amount of a radiolabelled iodo compound of Formula I of claim 30.

*add
B
act
C'*